Essex Property Trust, Inc. vs Merck & Co., Inc. — how do they compare? Essex Property Trust, Inc. trades at $282.11 (market cap $18.20B), while Merck & Co., Inc. trades at $129.71 (market cap $323.00B). The key difference: Merck & Co., Inc. is far larger — about 17.7× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays the higher dividend (3.66%). Which is the better fit depends on your goals.
| ESS | MRK | |
|---|---|---|
Market Cap | $18.20B | $323.00B |
Sector | Real Estate | Health |
52-Week High | $298.33 | $131.84 |
52-Week Low | $239.61 | $77.60 |
Enterprise Value | $24.80B | $369.77B |
Dividend Yield | 3.66% | 2.6% |
Signals from Pluang's Aura AI — not financial advice
ESS trades at $288.1, up 1.05% daily, with a neutral technical signal and support near $284. The stock shows strong profitability with a 21.48% net margin and recent Q2 2026 earnings miss on EPS but beat on FFO, leading to raised full-year guidance. Revenue growth is steady, reaching $1.89B in 2025, though net income declined to $670M from $742M in 2024.
Outlook is cautiously optimistic with a consensus price target of $305.86, implying ~6% upside. Risks include high debt levels (debt-to-asset ratio of 51.92% in 2024) and regional economic exposure. Analyst sentiment is mixed with 40% buy ratings, but institutional interest grew with Amundi increasing its stake in Q1 2026.
Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.
The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.
Trailing returns across standard periods
Latest headlines on both assets
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →